Lebwohl M, Ast E, Callen J P, Cullen S I, Hong S R, Kulp-Shorten C L, Lowe N J, Phillips T J, Rosen T, Wolf D I, Quell J M, Sefton J, Lue J C, Gibson J R, Chandraratna R A
Mount Sinai Medical Center, New York, New York 10029, USA.
J Am Acad Dermatol. 1998 May;38(5 Pt 1):705-11. doi: 10.1016/s0190-9622(98)70594-8.
A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed.
Our purpose was to compare the safety, efficacy, and duration of therapeutic effect of 12 weeks of once-daily tazarotene 0.1% and 0.05% gel with that of twice-daily fluocinonide 0.05% cream in the treatment of patients with plaque psoriasis.
Three hundred forty-eight patients with plaque psoriasis were enrolled and 275 patients completed a multicenter, investigator-masked, randomized, parallel-group clinical trial.
Both tazarotene gels were as effective as fluocinonide in reducing plaque elevation after 1 week of treatment, and tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of trunk/limb lesions at all study weeks except week 4. Tazarotene 0. 1% gel was similar to fluocinonide in reducing scaling of knee/elbow lesions at weeks 8 and 12. Fluocinonide had a significantly greater effect on erythema than tazarotene at weeks 2 through 8. However, treatments were not significantly different at week 12, and tazarotene demonstrated significantly better maintenance of therapeutic effect after cessation of therapy.
Tazarotene 0.1% and 0.05% gels were safe and effective in the treatment of mild-to-moderate plaque psoriasis.
已研发出一类新型的局部受体选择性乙炔类维甲酸，其中首个药物为他扎罗汀。
我们的目的是比较每日一次使用0.1%和0.05%他扎罗汀凝胶治疗12周与每日两次使用0.05%氟轻松乳膏治疗斑块状银屑病患者的安全性、疗效及治疗效果持续时间。
招募了348例斑块状银屑病患者，275例患者完成了一项多中心、研究者设盲、随机、平行组临床试验。
治疗1周后，两种他扎罗汀凝胶在减轻斑块隆起方面与氟轻松效果相当，在除第4周外的所有研究周，0.1%他扎罗汀凝胶在减轻躯干/肢体皮损鳞屑方面与氟轻松相似。在第8周和第12周，0.1%他扎罗汀凝胶在减轻膝/肘皮损鳞屑方面与氟轻松相似。在第2周至第8周，氟轻松在减轻红斑方面的效果显著优于他扎罗汀。然而，在第12周时治疗效果无显著差异，且他扎罗汀在停药后治疗效果的维持方面表现显著更好。
0.1%和0.05%他扎罗汀凝胶在治疗轻至中度斑块状银屑病方面安全有效。
